

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Group Art Unit – Unknown

In re

CERTIFICATION UNDER 37 CFR 1.10

Patent Application of

Sriram S. Iyer et al.


Application No.: Unknown


Confirmation No.: Unknown

Filed: January 26, 2004

Examiner: Unknown

I, Leslie Rector, hereby certify that this correspondence is being deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addressee," mailing Label Number EV 086435885 US, addressed to Mail Stop PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450


Signature


Date

“APPARATUS AND METHODS FOR
PREVENTING OR TREATING FAILURE OF
HEMODIALYSIS VASCULAR ACCESS AND
OTHER VASCULAR GRAFTS”

CLAIM CORRESPONDENCE

Mail Stop PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

After entry of the concurrently filed Preliminary Amendment, the claims of this application will correspond to the claims of Fischell *et al.* U.S. 6,534,693B2 (Application No. 09/772,693) and Fischell *et al.* '701 PAP as follows:

Claim No. in this Application

37
38
39
40
41
42
43
44
45
46
47
48

Claim No. in Fischell et al. '693

1
2
3
4
5
6
7
8
9
10
11
12

<u>Claim No. in this Application</u>	<u>Claim No. in Fischell et al. '693</u>
49	13
50	14
51	15
52	16
53	17
54	18
55	19
56	20
57	21
<u>Claim No. in this Application</u>	<u>Claim No. in Fischell Published Application, Pub. No. US2002/0055701 (Application No. 09/772,693)</u>
58	1
59	9
60	18
61	21
62	23


Proposed Count 1

A sheet of material adapted for implantation between tissues of a human body, the sheet of material including an attached anti-proliferative drug, and anti-proliferative drug being designed to reduce the generation of scar tissue, the anti-proliferative drug being selected from the group consisting of Rapamycin, tacrolimus (FK506), and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epitrimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.

Proposed Count 2

A sheet of material adapted for implantation between tissues of a human body, at least part of the sheet of material having an anti-proliferative drug attached, the action of the anti-proliferative drug being a reduction in the generation of scar tissue, the anti-proliferative drug being selected from the group that includes Rapamycin, Taxol, Alkeran, Cytosan, Leukeran, Cis-platinum, BiCNU, Adriamycin, Doxorubicin, Cerubidine, Idamycin, Mithracin, Mutamycin, Fluorouracil,

Methotrexate, Thoguanine, Toxotere, Etoposide, Vincristine, Irinotecan, Hycamptin, Matulane, Vumon, Hexalin, Hydroxyurea, Gemzar, Oncovin and Etophophos, tacrolimus (FK506), and the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-- rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.

Respectfully submitted,

Grady J. Frenchick
Reg. No. 29,018

Dated: January 26, 2004

Docket No.: 091401-9004

Michael Best & Friedrich LLP
One South Pinckney Street
P. O. Box 1806
Madison, WI 53701-1806
(608) 257-3501

Q:\client\091401\9004\B0306134.DOC